Previous studies suggested chalcones as antineoplastic drug candidates.
We synthesized a new chalcone derivative (E)-3-(4-methoxyphenyl)-2-methyl-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one, (CHO27) with an up to 1000-fold increased cytotoxic potency relative to its parent compound in cell culture assays. CHO27 at low nanomolar levels, inhibited prostate cancer (PCa) cell growth through cell cycle arrest and caspase-dependent apoptosis. Activation of p53 accounted for, at least in part, the growth inhibition by CHO27 in vitro. Furthermore, i.p. administration of CHO27 suppressed the growth of established PCa 22Rv1 xenograft tumors accompanied with p53 and p21(Cip1) induction. CHO27 may be a lead for development of new therapeutic agents for PCa.
Written by:
Zhang Y, Srinivasan B, Xing C, Lü J Are you the author?
Hormel Institute, University of Minnesota, 801 16th Avenue NE, Austin, MN 55912, U.S.A. and Chengguo Xing, Department of Medicinal Chemistry, University of Minnesota College of Pharmacy, 8-101 Weaver-Densford Hall, 308 Harvard Street SE, Minneapolis, MN 55455, U.S.A.
Reference: Anticancer Res. 2012 Sep;32(9):3689-98
PubMed Abstract
PMID: 22993307
UroToday.com Investigative Urology Section
